Risk Management

ROP: Anti-VEGF injection

ROP: Anti-VEGF Injection

These documents were revised in August, 2018. Click on the links below to access the forms.

• Consent for injection to treat ROP

• Consent for injection to treat ROP.Spanish

Articles on neurodevelopment after Avastin (bevacizumab) injection

OMIC and our ROP Task Force want to let you know of some new studies on the effect of Avastin on the infant’s neurodevelopment. We have revised our ROP consent forms to address this research.

Pediatrics published a report showing that the odds of severe neurodevelopmental disabilities was 3.1 times higher in infants treated with Avastin than those treated with laser. Another article[2] showed increased odds only in infants treated with both Avastin and laser.

Research is ongoing to determine if Avastin and other anti-VEGF drugs are safe. In the meantime, we all have to explain what we do know about these drugs to parents whose infants need treatment for ROP.

Questions?

Please contact OMIC Patient Safety Manager Anne M. Menke, RN, PhD, if you have any questions about our ROP forms or recommendations. You may reach Anne at 415-202-4651 or at amenke@omic.com.

Please contact our confidential Risk Management Hotline if you need help developing or revising protocols.

1. Warren J, Luu TM, Superstein R, et al. Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity. Pediatrics. 2016; 137 (4): e20153218. http://pediatrics.aappublications.org/content/early/2016/03/16/peds.2015-3218

2. Lien R, Yu M-H, Hsu K-H, Liao P-J, Chen Y-P, Lai C-C, et al. (2016) Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment. PLoS ONE 11(1): e0148019. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0148019